FUSMobile

FUSMobile advances noninvasive solutions for chronic painful conditions in order to improve the patient experience and clinical outcomes while reducing costs for healthcare providers and payers. The companys Neurolyser is a focused ultrasound treatment platform designed to relieve the suffering caused by a range of common conditions, including chronic lower back (facet joint) pain, knee and hip arthritis, sacroiliitis, and bone metastases. The completely noninvasive solution thermally ablates nerves without the risks, pain, high costs, and extensive training required by more invasive methods. FUSMobiles Neurolyser XR focused ultrasound device has finished its first-in-human study with excellent results and will soon enter pivotal clinical trials in pursuit of North American regulatory approval for facet joint arthritis, the first of many pain-related indications with potential benefits over currently available interventional pain treatments.

FUSMobile was founded in 2014 by Arik Hanannel (Co-Founder & CEO), Ron Aginsky (Co-founder & President).

FUSMobile operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Simulation & Imaging, Ultrasound. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

FUSMobile is based in Sderot HaNadiv 5, Haifa, Israel, North District. The company also has offices abroad.